Supreme Court Leaves FDA To Its Own Devices In Regulating Fraud Claims

The Supreme Court's Feb. 21 decision in Buckman Co. v. Plaintiffs Legal Committee defends off-label use as a vital "corollary" to FDA's regulatory scheme, while also investing sole authority in the agency to determine whether premarket submissions are fraudulent.